Adalimumab-adaz is a monoclonal antibody and biosimilar to the reference medicine adalimumab. It belongs to a group of medicines known as TNF inhibitors and works by selectively binding to and blocking tumour necrosis factor (TNF), a naturally occurring protein that plays an important role in causing inflammation. By reducing TNF activity, adalimumab-adaz helps decrease inflammation and relieve symptoms associated with various autoimmune and inflammatory diseases.

Adalimumab-adaz may be prescribed for conditions including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, plaque psoriasis, hidradenitis suppurativa, Crohn's disease, ulcerative colitis, and certain forms of uveitis. It is administered by subcutaneous injection, with the dosage and treatment schedule depending on the condition being treated and the patient's individual circumstances.

As with other TNF inhibitors, adalimumab-adaz can affect the immune system and may increase susceptibility to infections. Patients should be assessed for certain infections, including tuberculosis, before starting treatment and should be monitored throughout therapy. Common side effects may include injection-site reactions, respiratory infections, headache, and gastrointestinal symptoms.